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HIGH RATE OF DE NOVO CHRONIC GRAFT-VERSUS-HOST (CGVHD)
FOLLOWING BUSULFAN-FLUDARABINE CONDITIONING AND ALLOGE-
NEIC STEM CELL TRANSPLANTATION FROM A MATCHED-SIBLING
DONOR (MSD) FOR AML/MDS
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Andersson, B.S.1, Zhang, W.1, Rondon, G.1, Neumann, J.1,
Popat, U.R.1, Kebriaei, P.1, de Lima, M.1, Champlin, R.E.1 1 University
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Busulfan-fludarabine is increasingly used as a conditioning regi-
men for allogeneic stem cell transplantation (ASCT). Fludarabine
has complex immunologic effectswhichmay impact the development
of GVHD. Risk factors and outcomes of cGVHD in this setting have
not been determined. We retrospectively evaluated all consecutive
patients (pts) who received conditioning with IV Busulfan (130 mg/
m2 for 4 days) and Fludarabine (40 mg/m2 for 4 days) and ASCT
from a MSD at MD Anderson Cancer Center between 2001 and
2005. In a landmark analysis starting at day 1100, we estimated the
cumulative incidence (CI) of cGVHD (defined according to the re-
cent NIH consensus diagnostic criteria); evaluated risk factors for
overall and de novo cGVHD using Cox’s regression analysis; and eval-
uated the effect of cGVHDon outcome.104 pts were included in this
analysis. Median age was 46 years (12–65). 46% were females and
49% were in complete remission at the time of ASCT. Peripheral
blood (PB) was the stem cell source in 85% of pts. GVHD prophy-
laxis consisted of tacrolimus and methotrexate at standard doses.
The incidence of grade II-IV aGVHD was 18%. 89 pts were alive
on day 1100 without progression of their malignancy including 51
pts who had not developed aGVHD. With a median follow-up of
46 months in survivors, 57/89 pts developed cGVHD; half (n 5 29)
of these cases occurred de novo. The 3 years CI of de novo cGVHD
was 57% in the 51 pts without antecedent aGVHD. Time of onset
was later for de novo cGVHD compared with relapsing/progressive
cGVHD; median 195 days (115–693) vs. 143 days (100–639). The
use of PB was the only significant risk factor for development of
cGVHD (HRoverall5 3.3, P 0.01; HRde novo5 5.0, P 0.03). Recipient
age, recipient/donor sex andCMVserostatus, and disease status prior
to ASCT had no significant impact on the rate of cGVHD. On uni-
variate analysis considering cGVHD as time-dependent variable,
there was a trend toward an association of de novo cGVHD, but not
relapsing/progressive cGVHD, with a lower rate of disease progres-
sion (HR50.6,P0.4) andmortality (HR50.4,P0.1).Therewas also
a trend for more favorable overall survival (HR 5 0.4, P 0.08) and
non-relapse mortality (HR 5 0.3, P 0.2) in pts who developed de
novo compared with relapsing/progressive cGVHD. There is a high
frequencyof de novo cGVHDafter busulfan-fludarabine conditioning
and ASCT for AML/MDS. This suggests a shift in the epidemiology
of cGVHD that merits further consideration.340
EFFICIENT AND SELECTIVE PREVENTION OF GRAFT-VERSUS-HOST DIS-
EASE BY ANTIGEN-SPECIFIC TGF-INDUCED REGULATORY T CELLS
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Naturally occurring regulatory T cells (nTregs) suppress the de-
velopment of graft-versus-host disease and may spare graft-versus-
tumor effect. As nTreg is a rare cell population in a healthy individ-
ual, using in vitro expanded nTregs is a common strategy to test their
therapeutic potential in hematopoietic cell transplantation (HCT).
However, the concern of in vitro expanded nTregs may include their
stability of Foxp3 expression and suppressive function, survival in
vivo, and non-selective suppression of pre-activated nTregs. In this
study, we have used an alternative strategy to generate antigen-spe-
cific, induced Tregs (iTregs). CD41CD25- cells from OT-II TCR
transgenic, foxp3/gfp knock-in mice were induced to express Foxp3
by incubating with OVA peptide in the presence of TGFb.
CD41GFP1 cells were purified by sorting and used as iTregs while
CD41GFP- cells as controls. Their ability to prevent GVHD was
tested in a lethally irradiated murine BMT model: B6 / (B6 x
bm12)F1. In order to evaluate the specificity of iTregs, OVA-
expressing or non-expressing F1 recipients were directly compared.We found that iTregs (CD41GFP1) efficiently prevented GVHD
lethality in OVA1 recipients at a Treg:Teff ratio up to 1:8. The ef-
ficacy of these antigen-specific iTregs were significantly higher than
polyclonal iTregs from B6 donors as the latter could only partially
prevent GVHD and prolong recipient survival even at a 1:1 ratio.
In contrast to OVA1 recipients, antigen-specific iTregs failed to
prevent GVHD in OVA- recipients. As controls, CD41GFP- cells
had no effect on GVHD development in OVA- recipients, and
even exacerbated GVHD in OVA1 recipients compared to B6
CD41 effector cells alone. These results reveal the therapeutic po-
tential of antigen-specific iTregs to prevent GVHD efficiently and
selectively.341
EXPLORING T-CELL RECRUITMENT DURING THE EARLIER PHASE OF
GRAFT VS. HOST DISEASE IN VITRO
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Graft-versus-host disease (GVHD) is the major complication fol-
lowing allogeneic blood and marrow transplantation (BMT). Al-
though major advances have been achieved in understanding the
immunopathology of GVHD, the rate of success in the clinic has
been hampered by the inability to improve overall survival. T cell-
depletion of the hematopoietic stem cell inoculum has been proved
efficient in preventing GVHD, however, this treatment abolished
the graft-versus-leukemia (GVL) effect, also mediated by donor T
cells, resulting in significant increases in the rates of relapse. There-
fore, othermeans for separatingGVHDandGVLneed to be consid-
ered. Activation and recruitment of T cells to targeted organs during
GVHD is preceded by a well orchestrated, but yet unknown in
depth, sequence of events that involves the early secretion of chemo-
kines produced by a wide variety of cells, including dendritic cells,
mast cells, T cells and their primary targets duringGVHD, epithelial
cells, in the skin and the gastrointestinal tract. In this study, we take
advantage of our recently developed in vitro model of allogeneic T
cell/epithelial interactions to investigate this less explored aspect of
GVHD. Using a high throughput multicytokine assay, we examined
the secretion of different chemokines in cocultures of skin primary
epithelial cells (pEC), obtained from C.B10-H2b (BALB.B) mice,
with allogeneic T cells, derived from minor histocompatibility anti-
gen allogeneic C57Bl/6 (B6) mice. In addition to IFN-g and IL-12,
we detected the presence of MCP-1/CCL2, MIP-1a/CCL3,
RANTES/CCL5 and GM-CSF by 7 days after the addition of the
allogeneic T cells. Although we do not know yet in detail whether
T cells, epithelial cells, or both are responsible for the secretion of
the chemokines in our system, their level was dependent on the
amount of T cells added to the cocultures (p\0.03). However, we
found that in the absence of T cells, conditioning of the pEC by ex-
posure to 11 Gy of g-irradiation induced the secretion of 109.6 pg/
ml MCP-1 and 21.7 pg/ml RANTES within 24 hours. Thus, our
preliminary data suggests that the conditioning of epithelial cells,
alone, is enough to induce secretion of chemokines, which in turn
could induce T cell recruitment to the site before any damage to
the epithelial cells can be visualized, leading subsequently to an am-
plification cascade governed by chemokine secretion from both tar-
get and effector cells.342
WHAT IS THE ROLE FOR REGULATORY T-CELLS AFTER NONMYELOABLA-
TIVE CONDITIONING?
Humblet-Baron, S., Castermans, E., Vanbellighen, J.-F., Hannon, M.,
Jacobs, N., Willems, E., Ormenese, S., Beguin, Y., Baron, F. University
of Lie`ge, Lie`ge, Belgium
Purpose: We investigated the association between regulatory
T-cell (Treg) levels and chronic graft-versus-host disease (GVHD)
after allogeneic hematopoietic stem cell transplantation (HCT)
following nonmyeloablative conditioning.
Methods: Data from 74 patients given nonmyeloablative condi-
tioning as treatment for hematological malignancies or renal cell
carcinomas were analyzed. Conditioning regimens consisted of
